As HHS Secretary, Nominee Burwell Would Preside Over ACA Policy Revisions
This article was originally published in The Pink Sheet Daily
Executive Summary
OMB Director Sylvia Burwell is nominated to take the helm at HHS, where she would manage future evolutions in the exchange plans, including possible changes to drug coverage policies that would be effective in 2016.
You may also be interested in...
Track-And-Trace: With Deadline A Year Away, Some Lessons From Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.